You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
輝瑞(PFE.US)及阿斯利康(AZN.US)擬在華推出多個新藥或適應症申請
阿思達克 03-26 14:41
輝瑞(PFE.US)董事長兼行政總裁艾伯樂在北京出席「投資中國」活動致詞時提到,對中國的創新藥物開發前景感興趣,計劃明年前在中國提交17個新藥或適應症申請。阿斯利康(AZN.US)行政總裁蘇博科亦稱,目前研發管線逾200個項目,預計未來5年將在中國推出約100個新藥及適應症申請。 另外,艾伯樂較早時表示,中國市場潛力巨大,存在著許多機會,相信在數年內中國就會成為生物科技創新的尖端。目前中國已成為輝瑞僅次於美國的第二大市場,希望各方能加強合作,認為生物科技不斷發展,AI將改變研發方式,亦會改變價值鏈上的每一環。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account